On August 15, 2022, Rocgene (Beijing) Technology Co., Ltd. (“Rocgene”) officially entered into a strategic cooperation with Shanghai Jienuo Bio-Tech Co., Ltd. (“CNBG Jienuo”), a subsidiary of China National Biotec Group. Leveraging their respective technological strengths and advantages, the two parties will jointly promote the clinical application of automated, intelligent, and multiplex fluorescence PCR technology in fields including tumor methylation early screening and multi-target pathogen detection, providing users with richer and more comprehensive product solutions through long-term in-depth collaboration.

As the first step of the collaboration, the two parties will combine CNBG Jienuo’s newly approved product – the first domestic medical device certificate for cervical cancer HPV primary screening methylation triage: Methylation Detection Kit for Human ASTN1, DLX1, ITGA4, RXFP3, SOX17, ZNF671 Genes (Fluorescence PCR) (“Gong An Li®”). Together, they will build an integrated solution for early tumor methylation screening covering instrument + reagent + intelligent software, making molecular diagnosis of tumors more efficient, simple, and accessible.

Mr. Guo Qiuzhen
Founder & CEO, Rocgene

“CNBG Jienuo is among the first companies to obtain medical device registration certificates for COVID-19 nucleic acid detection kits and the first domestic certificate for Gong An Li® in cervical cancer HPV primary screening methylation triage. This fully demonstrates CNBG Jienuo’s technological advantages and innovation capabilities in nucleic acid detection for tumors and multiplex pathogens. We are honored to cooperate with such an outstanding team. We hope that through mutual empowerment and complementary strengths, we will launch higher-quality products and services and better promote the development of China’s molecular diagnostics industry.”

Mr. Xia Xiaokai
General Manager, CNBG Jienuo

“As a core domestic supplier of PCR technology and products, Rocgene’s Archimed Series Real‑Time PCR Systems have achieved large‑scale market deployment and gained excellent user feedback in a short time, thanks to its profound technical accumulation and strong industrialization system. Based on close cooperation during the pandemic, both sides have recognized shared values: rigor, pragmatism, customer orientation, and technological innovation. Through further strategic cooperation and technological & product complementarity, we believe we will actively contribute to the rapid development of the domestic IVD industry.”

During the pandemic, Rocgene and CNBG Jienuo relied on their respective strengths in fluorescence PCR instruments, nucleic acid detection reagents, mobile laboratory solutions, and testing services to collaborate closely on the frontline of epidemic prevention. They successively supported large‑scale nucleic acid testing bases in Shanghai, Beijing, Macao, Lanzhou and other regions, contributing to local pandemic control and accumulating rich cooperation experience.

About CNBG Jienuo

Shanghai Jienuo Bio-Tech Co., Ltd. is affiliated with China National Biotec Group (CNBG), Sinopharm, serving as the unified medical diagnosis operation platform under CNBG. CNBG Jienuo was among the first to successfully develop COVID-19 nucleic acid detection kits and obtain medical device registration certificates issued by NMPA.

Positioned as a global leading industrialization and transformation platform for cutting‑edge technologies in the IVD sector, CNBG Jienuo focuses on multiplex detection of infectious pathogens and molecular diagnosis of tumors. Its main products include cervical cancer methylation detection kits, single‑tube multiplex nucleic acid detection kits for respiratory pathogens, encephalitis/meningitis, enteric pathogens, central nervous system infections, prenatal and reproductive tract infections, serving hospitals, CDCs, inspection and quarantine bureaus, etc.

About Rocgene

Founded in 2016, Rocgene (Beijing) Technology Co., Ltd. is a high‑tech biotechnology company established by scientists and industry professionals, driven by core technologies. Rocgene is committed to translating cutting‑edge life science technologies into clinically applicable medical research products and developing proprietary research and molecular diagnostic products with independent intellectual property rights.

Rocgene has been accredited as a National High-Tech Enterprise and Zhongguancun High-Tech Enterprise. It has applied for 6 invention patents, 6 utility model patents, and obtained 16 software copyrights. The company owns a clean production workshop of over 10,000 ㎡ in Xuzhou High-Tech Zone. Upholding the courage to surpass itself and the ambition to excel, Rocgene aspires to be a forward‑looking industry leader.